Keith Lenden

Keith earned an MBA from UC Berkeley's Haas School of Business and was a Price Institute for Entrepreneurial Studies Venture Capital Fellow. He also studied engineering at Dartmouth College's Thayer School. Keith is married with two daughters and enjoys live music, hiking, skiing and woodworking.

Keith Lenden joined ARCH Venture Partners as a Venture Partner in 2017. He is a seasoned entrepreneur and leader in the biotechnology and pharmaceutical space with a proven track record in company formation, executive and project leadership, business and corporate development/venture, alliance management, and corporate and market strategy. 

​

Keith has co-founded two successful biotech companies: Receptos, Inc., a S1P1 biology and GPCR drug discovery company acquired by Celgene for $7.2 billion in 2015; and Abide Therapeutics, Inc., a cannabinoid biology and serine hydrolase drug discovery company that entered into a build-to-buy partnership with Celgene in 2014. Keith has served in a wide range of executive and product leadership roles for both public and private biopharmaceutical companies over the years including Esperion Therapeutics, Inc., Maxygen, Inc., Acologix, Inc. and Genteric, Inc. Keith started his career in biotechnology as a consultant at LEK Consulting.

As a member of Class 16, Keith served his fellowship at both Maxygen and Abide Therapeutics under the mentorship of James Sulat (Maxygen) and Robert Nelsen (ARCH Venture Partners; Mentor Class 4). 

​

Upon graduation, Keith was presented with the Jeff Timmons Memorial Award, recognizing his outstanding contributions to the Kauffman Fellows Program.